Amelia Beatty, NP, CWCN-AP joins MedSurgPI
MedSurgPI is proud to introduce a wound healing consultant, Amelia Beatty, NP, CWCN-AP. Amelia has worked in Wound Care at Duke University Hospital Clinics, Durham, NC since 2012. She certified as a Wound Care Nurse – Advance Practiced having obtained her certification from the University of Washington in 2013. Amelia has surgical wound healing knowledge gained from former positions in Trauma and Acute Pain Management as well as Plastic Surgery. Amelia integrated the wound management theory and concepts for the medical and surgical wound care population she serves.
MedSurgPI welcomes Dr. Lee Schacter, Ph.D., M.D.
MedSurgPI proudly welcomes Dr. Lee Schacter, Ph.D., M.D. to MedSurgPI. Dr. Schacter is board certified in medical oncology and has extensive experience in all phases of cancer drug development and trial conduct. He has worked with cytotoxics, targeted therapies, immune therapies, antibody drug conjugates and other treatment modalities. He is currently directing and funding a research program to discover the compound(s) that cause cachexia in some cancer patients. Dr. Schacter has worked at major pharmaceutical biotech companies including Pfizer and Astra-Zeneca.
Microbac and MedSurgPI Join Forces to Offer Expansive Product Development Consulting for the Pharmaceutical Market
FEBRUARY 5, 2018 (PITTSBURGH, PA) – Microbac Laboratories, Inc. today announces a new strategic partnership to offer clients the R&D consulting services of MedSurgPI - a team of commercially experienced pharmaceutical and medical device consultants.
“Whereas our R&D consulting services provide understanding of product quality and safety through many steps of product development, MedSurgPI picks up where our expertise leaves off,” explains Microbac CEO, Cabot Earle. “Their consulting team has the market intelligence and experience to dive deep into the complete biomedical product development cycle. This partnership expands informed project guidance to cover all aspects of pharmaceutical and medical device product development from R&D to accredited testing and medical strategy.”
The MedSurgPI team brings unique experience in the scientific, technical, medical and commercial issues that Microbac customers face in the biomedical market. From regulatory demands, to clinical trials, ongoing manufacturing, and troubleshooting, their experts are experienced in end-to-end product development demands.
“Our team will help Microbac clients strategize and coordinate solutions to successfully navigate the landscape of product development,” explains MedSurgPI principal, Dr. Peter Johnson. “We believe in product optimization, quality assurance auditing, and preventing problems before they arise. This is a peace of mind we look forward to bringing to Microbac clients.”
Microbac also plans to offer MedSurgPI services to their food, medical food, and nutritional supplements clients as valuable guidance through diverse product development requirements.
“We see this as a win-win,” explains Earle. “Our team now has the opportunity to help clients go even further, and our clients will benefit from trusted guidance to accomplish more than ever.”
ABOUT MICROBAC LABORATORIES, INC.
Microbac is an independent laboratory testing company committed to delivering quality measurement data and optimal customer experience for our clients. Serving the food, life sciences, and environmental markets, we partner with our clients to help them innovate and produce with confidence, and in compliance. Since 1969, Microbac has helped to assure the quality, health and safety of products that impact consumers every day. microbac.com
MedSurgPI provides its clients with supplemental guidance in the areas of product design, CMC consultation, quality, regulatory science, toxicology, project management, clinical development, clinical trials consultation, reimbursement and Health Economic and Outcomes Research. MedSurgPI coordinates these services by functioning as the client’s product development consultants. medsurgpi.com
Technology Commercialization Group, LLC (TCG) Announces a Strategic Partnership with MedSurgPI, LLC
January 11, 2018
TCG and MedSurgPI, two North Carolina-based life sciences consulting firms, today announced the formation of a strategic partnership to provide highly complementary skills in support of their pharmaceutical, biotechnology and medical device client companies. TCG offers strategic transaction advisory services as well as experienced C-level executives acting as interim operational and commercial managers to grow life sciences companies. MedSurgPI provides its clients with highly experienced clinician-executives acting as medical officers for strategic planning, product development, medical monitoring, safety and pharmacovigilance. The ability of the two firms working together to support clients in executing their business objectives across their commercial and medical operations makes the partnership especially attractive.
To learn more about this partnership, you may contact TCG’s Ken West at phone (919) 941-0700 x108 or E-mail firstname.lastname@example.org or contact MedSurgPI’s Peter Johnson, MD at (919) 807-9132 or E-mail email@example.com.
Founded in 2015 by two highly experienced physician-executives, MedSurgPI works with biopharmaceutical, medical device, diagnostic companies and CROs. We provide commercially adept medical consulting in product development, medical affairs, including medical monitoring, clinical trial planning/optimization and support a full range of medical communications. MedSurgPI physicians can serve as medical officers such as chief medical officer, or product development officer. Our team members have been involved with numerous successful US and EU product approvals. Our medical affairs team has helped marketing campaigns, both at launch and when refocusing. MedSurgPI provides a cost-effective way of having senior medical leadership on your team at critical points in your development cycle.
Founded in 1998, TCG serves life science companies, including medical device, pharmaceutical, and biotechnology companies from its headquarters in the Research Triangle Park region of North Carolina, USA and offices in Heidelberg, Germany. TCG leads and advises transactions, including licensing, strategic partnerships, distribution agreements, asset sales, financings, and acquisitions. TCG also provides interim management, when an experienced executive is needed for a critical project, to enter a new market, to develop a new strategy, or to refocus a company. TCG’s approach is different from other firms in that only senior TCG partners, with over 25 years of life science industry experience, lead assignments. TCG has developed experience in bringing European based companies commercialize their products in the US. TCG has successfully completed dozens of life science projects and assignments.
AlphaMD and MedSurgPI have entered into a partnership to provide comprehensive Product Development and Commercialization with Medical Affairs Services to clients worldwide.
September 1, 2017
This service is a proprietary process to assist start-ups and established Life Science companies launch their drug, diagnostic and medical device products successfully from concept through launch and post-market surveillance. It encompasses proof-of-concept studies, clinical trial assistance, market research, product development, health economics and outcomes research services, a successful launch, data analytics and pharmacovigilance.
North Carolina Biotechnology Center
Life Sciences Forum 2017 | September 18 | 4:30 pm
Critical Aspects of Regenerative Medicine
Panel includes MedSurgPI's Principal Peter Johnson, M.D.
Article by Gerry L. Klein, M.D. & Maxwell O. Clark appearing in:
The Journal for Clinical Studies | Volume 9, Issue 3 | June 2, 2017
The Pharmacy Adjudicated Clinical Study Supply Process Decreases Risk, Cuts the Cost and Improves the Efficiency when Providing Subjects Unblinded Clinical Study Supplies